Literature DB >> 7805358

Bacteriologic characteristics and antimicrobial susceptibility of 70 clinically significant isolates of Streptococcus milleri group.

J L Gómez-Garcés1, J I Alós, R Cogollos.   

Abstract

The phenotypical characteristics of 70 clinical isolates of Streptococcus milleri group were analyzed. Association of the three species with particular sites of isolation could not be demonstrated in all cases, but S. anginosus strains predominated in abdominal area, while S. intermedius was isolated mainly in hepatic abscesses. Penicillin G and other beta-lactams showed good in vitro activity against these streptococci, whereas > 10% exhibited resistance to erythromycin and clindamycin. Resistance to tetracycline reached almost 40%. All of the isolates were uniformly susceptible to vancomycin, chloramphenicol, and trimethoprim.

Entities:  

Mesh:

Year:  1994        PMID: 7805358     DOI: 10.1016/0732-8893(94)90115-5

Source DB:  PubMed          Journal:  Diagn Microbiol Infect Dis        ISSN: 0732-8893            Impact factor:   2.803


  12 in total

1.  Prevalence of macrolide resistance genes in clinical isolates of the Streptococcus anginosus ("S. milleri") group.

Authors:  J A Jacobs; G J van Baar; N H London; J H Tjhie; L M Schouls; E E Stobberingh
Journal:  Antimicrob Agents Chemother       Date:  2001-08       Impact factor: 5.191

2.  Effect on polymorphonuclear cell function of a human-specific cytotoxin, intermedilysin, expressed by Streptococcus intermedius.

Authors:  M G Macey; R A Whiley; L Miller; H Nagamune
Journal:  Infect Immun       Date:  2001-10       Impact factor: 3.441

3.  Species belonging to the "Streptococcus milleri" group: antimicrobial susceptibility and comparative prevalence in significant clinical specimens.

Authors:  C Bantar; L Fernandez Canigia; S Relloso; A Lanza; H Bianchini; J Smayevsky
Journal:  J Clin Microbiol       Date:  1996-08       Impact factor: 5.948

Review 4.  Emerging resistance to antimicrobial agents in gram-positive bacteria. Enterococci, staphylococci and nonpneumococcal streptococci.

Authors:  M G Cormican; R N Jones
Journal:  Drugs       Date:  1996       Impact factor: 9.546

5.  Antibiotic susceptibilities of genetically characterized Streptococcus milleri group strains.

Authors:  M Tracy; A Wanahita; Y Shuhatovich; E A Goldsmith; J E Clarridge; D M Musher
Journal:  Antimicrob Agents Chemother       Date:  2001-05       Impact factor: 5.191

6.  Lancefield grouping and smell of caramel for presumptive identification and assessment of pathogenicity in the Streptococcus milleri group.

Authors:  O Brogan; J Malone; C Fox; A S Whyte
Journal:  J Clin Pathol       Date:  1997-04       Impact factor: 3.411

7.  Genotypic and phenotypic characterization of "Streptococcus milleri" group isolates from a Veterans Administration hospital population.

Authors:  J E Clarridge; C Osting; M Jalali; J Osborne; M Waddington
Journal:  J Clin Microbiol       Date:  1999-11       Impact factor: 5.948

8.  Prospective study of Streptococcus milleri hepatic abscess.

Authors:  J Corredoira; E Casariego; C Moreno; L Villanueva; J Varela; A Rodríguez; P Alonso; A Coira
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1998-08       Impact factor: 3.267

Review 9.  What happened to the streptococci: overview of taxonomic and nomenclature changes.

Authors:  Richard Facklam
Journal:  Clin Microbiol Rev       Date:  2002-10       Impact factor: 26.132

10.  Identification of "Streptococcus milleri" group isolates to the species level with a commercially available rapid test system.

Authors:  C E Flynn; K L Ruoff
Journal:  J Clin Microbiol       Date:  1995-10       Impact factor: 5.948

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.